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Abstract
Lupus enteritis is a rare and poorly understood cause of abdominal pain in patients with systemic lupus
erythematosus (SLE). In this study, we report a series of 7 new patients with this rare condition who were referred
to French tertiary care centers and perform a systematic literature review of SLE cases fulfilling the revised ACR
criteria, with evidence for small bowel involvement, excluding those with infectious enteritis. We describe the
characteristics of 143 previously published and 7 new cases. Clinical symptoms mostly included abdominal pain
(97%), vomiting (42%), diarrhea (32%) and fever (20%). Laboratory features mostly reflected lupus activity: low
complement levels (88%), anemia (52%), leukocytopenia or lymphocytopenia (40%) and thrombocytopenia (21%).
Median CRP level was 2.0 mg/dL (range 0–8.2 mg/dL). Proteinuria was present in 47% of cases. Imaging studies
revealed bowel wall edema (95%), ascites (78%), the characteristic target sign (71%), mesenteric abnormalities (71%)
and bowel dilatation (24%). Only 9 patients (6%) had histologically confirmed vasculitis. All patients received
corticosteroids as a first-line therapy, with additional immunosuppressants administered either from the initial
episode or only in case of relapse (recurrence rate: 25%). Seven percent developed intestinal necrosis or perforation,
yielding a mortality rate of 2.7%. Altogether, lupus enteritis is a poorly known cause of abdominal pain in SLE
patients, with distinct clinical and therapeutic features. The disease may evolve to intestinal necrosis and perforation
if untreated. Adding with this an excellent steroid responsiveness, timely diagnosis becomes primordial for the
adequate management of this rare entity.
Keywords: Systemic lupus erythematosus, Abdominal pain, Lupus enteritis, Small bowel disease, Vasculitis
Introduction
Abdominal pain is a frequent symptom in patients diag-
nosed with systemic lupus erythematosus (SLE) [1].
Apart from the classic causes of acute abdomen, the
physician should be aware of infectious complications
linked to immunosuppressive treatments as well as more
disease-specific conditions such as pancreatitis [2,3],
intestinal pseudo-obstruction [4] and lupus enteritis
(Table 1) [5]. The frequency of this complication is cur-
rently unknown, as lupus enteritis has been reported to
be either the most common [6] or contrarily a rare [7]
cause of abdominal pain in SLE patients. Furthermore,
nomenclature is confusing, with lupus enteritis, mesen-
teric arteritis, intestinal vasculitis, enteric vasculitis, me-
senteric vasculitis, lupus peritonitis and abdominal
serositis among others used to name seemingly the same
condition [8]. In the BILAG 2004, lupus enteritis is de-
fined as either vasculitis or inflammation of the small-
bowel, with supportive image and/or biopsy findings,
which underlines the broad spectrum of the disease.
Therefore, lupus enteritis should be considered a poorly
defined cause of abdominal pain in SLE. Here, we report
7 new cases of lupus enteritis and perform a systematic
review of the literature to describe in depth the patho-
genic, clinical, laboratory and radiological aspects of this
rare SLE feature, as well as the response to treatment
and long-term follow-up.
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Study design and patient selection
The current multicenter retrospective study is based on
7 consecutive patients with lupus enteritis, referred to
two tertiary care centers (department of internal medi-
cine, Hôpital Pitié-Salpêtrière and department of clinical
immunology, Hôpital Saint Louis, Paris, France) between
January 1990 and December 2011. These patients were
identified from computerized databases, which records
the main diagnoses for each patient, and from an elec-
tronic review of all medical records. The databases were
searched for the International Classification of Diseases
10th Revision (ICD-10) code for SLE (code M32) as well
as for “Lupus enteritis”. Additional cases were contrib-
uted after hand-search of patient files. The medical re-
cords of all patients identified were reviewed by 2
physicians (PJ and LA) to ensure that patients fulfilled
the revised ACR criteria for SLE [9,10] and had clinical
and radiological evidence for small bowel involvement
(Small bowel wall edema, abnormal bowel-wall enhance-
ment [double halo or target sign], dilatation of bowel
lumen and mesenteric abnormalities such as engorge-
ment of mesenteric vessels, increased number of visible
vessels [comb’s sign], and increased attenuation of me-
senteric fat). Patients with infectious causes of enteritis
were excluded.
Data collection
We collected data using a form specifically designed for
this study, recording information about demographics,
comorbidities, clinical history of lupus enteritis, imaging,
laboratory data, histology, treatment and outcome.
Literature review
We also performed a systematic literature review by
searching PubMed for articles published between 1964
and July 2012, combining the Mesh terms “systemic
lupus erythematosus”, “enteritis”, “vasculitis”, “serositis”,
“digestive system”, “intestines” and “mesentery”. We fur-
ther searched the reference lists of identified articles for
additional papers. All papers identified were reviewed by
2 physicians (PJ and LA) to ensure that all patients ful-
filled the revised ACR criteria for SLE and had clinical
and radiological evidence for small bowel involvement
(as described above). Case reports on infectious causes
of enteritis and papers with insufficient clinical informa-
tion were excluded.
Statistical analysis
Quantitative variables were expressed as mean and
standard deviation or as median and range while qualita-
tive variables were expressed as numbers and percent-
ages. Statistical analysis was performed using GraphPad
Prism, version 5.0 (GraphPad, San Diego, CA).
Case reports
Case #1
An 18-year old female was diagnosed in 2003 with lupus
enteritis on basis of acute abdominal complaints and a
typical target image (small bowel wall edema with abnor-
mal bowel-wall enhancement) on abdominal CT-scan.
At that time she received prednisolone 5 mg and HCQ
400 mg on a daily basis as she had been diagnosed with
lupus 2 years earlier based on cutaneous involvement,
cytopenia, and presence of antinuclear antibodies with
positive search for anti-dsDNA antibodies. She was
administered IV methylprednisolone with rapid improve-
ment. She was recently reevaluated for recurrent abdo-
minal pain and nausea. Physical examination on admission
was unremarkable. Biology showed a lupus anticoagulant
(without history of thrombosis or abortion), positive ANA
and ds-DNA without other signs of active SLE (SLEDAI 1).
A CT scan was normal. Treatment was unchanged. No re-
currence could be objectified until present.
Case #2
A 31 year-old female had been diagnosed with lupus in
2000 when she presented with arthritis, malar rash, peri-
carditis, positive ANA and ds-DNA antibodies. In 2006,
she developed acute abdominal pain with nausea and
vomiting. At that time, her daily treatment consisted of
prednisone 10 mg per day and HCQ 400 mg per day.
She presented no clinical signs of lupus activity (SLEDAI
3). An abdominal CT-scan revealed small bowel edema
with target sign. She received IV methylprednisolone
(1 g per day for 2 days) and tapered oral prednisone,
with prompt clinical and radiological recovery (the
follow-up CT-scan at 10 days was normal). However, she
presented a similar episode 8 months later while on
prednisone 5 mg per day and HCQ. She was again
Table 1 Leading causes of acute abdominal pain in SLE
patients
Non-SLE related SLE related
Appendicitis Lupus enteritis
Lithiasic cholecystitis Pancreatitis
Peptic ulcer Pseudo-obstruction
Acute pancreatitis Acalculous cholecystitis
Retroperitoneal hematoma Mesenteric thrombosis
Ovarian pathology Hepatic thrombosis
Diverticulitis Medication (NSAIDs, MMF,
steroids, HCQ…)
Adhesions, intestinal occlusion Colon perforation (vasculitis)
Infectious Enteritis
Pyelonephritis
CMV colitis
SLE: Systemic Lupus Erythematosus; NSAIDs: Nonsteroidal anti-inflammatory
drugs; MMF: mycophenolate mofetil; HCQ: hydroxychloroquine.
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administered IV methylprednisolone (1g per day for 3
days), and a long-term treatment with MMF 2 g per day
was initiated. MMF was halted in 2008 because of a
pregnancy wish, with no recurrence of lupus enteritis
until present.
Case #3
A 47 year-old female, diagnosed with SLE at the age of
43, was admitted in 2007 with anorexia, weight loss and
a 1-month history of asthenia, intermittent fever, nausea,
vomiting and arthralgia. In this patient, SLE was diag-
nosed based on a history of arthritis, oral ulcers, lupus
nephritis, and presence of antinuclear antibodies with
positive search for anti-dsDNA antibodies. At admission,
her abdomen was mildly tender. Relevant biology results
included lymphocytopenia (1472/mm3), positive antinu-
clear antibody (ANA) at 1:1600, highly elevated anti ds-
DNA (> 300 U/mL, normal range 0–27 U/mL), low serum
albumin (28 g/L), normal C3 complement fraction
(0.78 g/L, normal range: 0.72-1.39 g/L), low C4 (0.09 g/L,
normal range; 0.15-0.32 g/L) and CH50 (63%, normal
range: 70-130%), increased proteinuria (2.25 g/L) with
normal creatinine value, and suppressed TSH; C-reactive
protein (CRP) were normal, antiphospholipid (aPL) anti-
bodies were negative. She was diagnosed with SLE flare
with class III + V lupus nephritis and associated Graves
hyperthyroidism. The Systemic lupus erythematosus
disease activity (SLEDAI) score was 19. She was started on
IV methylprednisolone (1g per day for 3 days) and a con-
comitant first dose of IV cyclophosphamide (CYC) was
administered, followed by oral prednisone (1 mg/kg/day).
Four days later, she developed acute abdominal pain and
vomiting. Abdominal CT-scan revealed thickened wall
with target sign of the terminal ileum, ascites and periton-
eal enhancement after intravenous (IV) contrast (Figure 1).
Concomitant lupus enteritis was diagnosed and IV meth-
ylprednisolone was resumed (40 mg per day). Abdominal
pain disappeared over the next three days and oral pred-
nisone could be reinstated six days later. She further re-
ceived 11 monthly cycles of CYC (IV 750 mg/m2) for
lupus nephritis. Finally, she regained weight and on
maintenance therapy with hydroxychloroquine (HCQ)
400 mg per day, mycophenolate mofetil (MMF) 2 g per
day and oral prednisone slowly tapered to 5 mg per day
no recurrence of abdominal pain was observed until
present (December 2011).
Case #4
In 2008, a 27-year old female was transferred because of
severe generalized edema that developed 1 month after
delivery at 35 weeks of a healthy girl. In this patient,
diagnosis of SLE was based on arthritis, cytopenia, and
presence of antinuclear antibodies with positive search
for anti-dsDNA antibodies. She had been also diagnosed
Figure 1 Imaging findings of lupus enteritis. Panel A: Edematous small-bowel wall (ileum) with the characteristic target sign (abnormal
bowel-wall thickening and enhancement) and ascites. Panel B: Small bowel distention with engorgement of mesenteric vessels and ascites.
Panel C. Edematous ileum wall with engorgement of mesenteric vessels and increased number of visible vessels (comb’s sign).
Panel D: Bowel-wall thickening and enhancement (target sign). All the above described abnormalities are non-specific and can also be seen in patients
with pancreatitis, mechanical bowel obstruction, peritonitis, or inflammatory bowel disease, all of which may mimic intestinal ischemia.
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with class V lupus nephritis in 2007 and treated with
MMF and cyclosporine that were interrupted 3 months
later because of pregnancy. On admission, she was on
prednisone 10 mg per day. She presented predominant
abdominal complaints with pain and diarrhea. Physical
examination revealed bilateral leg edema and tender ab-
domen. Biology showed leukopenia with neutropenia
(560/mm3) and heavy proteinuria (30 g/L). She had ac-
tive lupus (SLEDAI 10). Her abdominal CT-scan showed
edema of the proximal jejunum with target sign and
moderate ascites. Treatment consisted of IV methylpred-
nisolone 1 g per day for 3 days, tapered oral prednisone
0.5 mg/kg and long-term HCQ 400 mg per day and
MMF 2 g per day with no relapse until present.
Case #5
A 28 year-old woman presented in 2008 with a 2-day
history of abdominal pain, diarrhea and vomiting. At
that time she received low dose corticosteroids (5 mg/
day of prednisone), HCQ and Coumadin on a daily basis.
She was diagnosed with SLE based on arthritis, serositis,
cutaneous involvement, and presence of antinuclear
antibodies with positive search for anti-dsDNA anti-
bodies and aPL syndrome at the age of 18 when she
presented pulmonary embolism and lupus anticoagulant
was detected. Biology was notable for low CH50 and C3
complement levels and INR 4.2. An abdominal CT re-
vealed intestinal edema with target sign and moderate
ascites without mesenteric thrombosis. She received
1000 mg IV methylprednisolone for 3 days, with rapid
improvement. Because she presented 2 similar episodes
over the next 6 months a treatment with MMF and later
AZA was installed, however she continued to present
chronic intermittent abdominal pain and diarrhea. Mul-
tiple repeat imaging and extensive abdominal workup
were normal. She is currently treated with HCQ, low dose
steroids (5 mg/day of prednisone) and Coumadin and
continues to present sporadic abdominal discomfort.
Case #6
A 28-year-old woman presented in 2008 with abdominal
pain and vomiting. She was diagnosed with SLE 10 years
before because of arthritis, lupus nephritis, and presence
of antinuclear antibodies with positive search for anti-
dsDNA antibodies. She had trouble with compliance and
she was not regularly taking medication for the last two
years. In retrospect, she mentioned a similar episode 1
year before which had been successfully treated with oral
steroids. Biology was remarkable for low complement,
lymphocytopenia and significant proteinuria. Abdominal
CT revealed small bowel edema with target sign. She
was treated with IV methylprednisolone 1 g/day for 3
days with rapid improvement. Oral prednisolone was
rapidly tapered and daily HCQ was added. She was sub-
sequently lost for follow up.
Case #7
A 48-year-old woman presented in 2010 with a two-day
history of abdominal pain and vomiting. She was on
daily low dose corticosteroids and HCQ. She had been
diagnosed with SLE 2 years before, when she presented
with arthritis, cutaneous involvement, cytopenia, and
presence of antinuclear antibodies with positive search
for anti-dsDNA antibodies. Physical examination was re-
markable for abdominal guarding and extensive livedo
reticularis. Biology revealed low complement but no argu-
ment for hemolysis. Abdominal CT showed edema with
target sign of the proximal ileum. She received prednisone
2 mg/kg/day with rapid improvement. Daily MMF was
added a few months later, when she presented a severe cu-
taneous flare because it was felt at that time that she
would benefit from additional immunosuppressive therapy
as a manner to better control disease activity. She had no
recurrence of abdominal pain until present.
Review
Patients’ characteristics
Including the 7 new cases, 150 patients (111 women; 8
men, 31 not mentioned) fulfilling our inclusion criteria
for lupus enteritis have been reported in the literature
[1,11-48]. Mean age at diagnosis of lupus enteritis was
32.5 years, the youngest patient was 13 and the oldest
was 72 years old. Male–female ratio was 1/14. In 19 of
the 146 (13%) patients in whom this information was
available, SLE was diagnosed simultaneously with the
first episode of enteritis. Two patients presented enteritis
before diagnosis of SLE [14,20]; one presented a necro-
tizing vasculitis of the ileum 1 month before diagnosis of
SLE, another had lesions in the small intestine on cap-
sule endoscopy 4 months before diagnosis of SLE. When
patients were already diagnosed with SLE (n = 126), me-
dian time from SLE diagnosis to first episode of enteritis
was 60 months (range: 5 months to 20 years).
Clinical features
The most frequent symptoms were focal or diffuse ab-
dominal pain (146/150; 97%), ascites (71/91: 78%, clin-
ical or radiological), nausea (36/74; 49%), vomiting (31/
74; 42%), diarrhea (24/74; 32%) and fever (15/74; 20%)
(Table 2). A surgical abdomen with guarding and rebound
was found in 33/105 cases (31%). Four patients had clinic-
ally evident digestive bleeding. Fifty-three patients (35%)
had other clinical features of active SLE, including lupus
nephritis (n = 37), serositis (n = 15), neuropsychiatric man-
ifestations (n = 11), rash (n = 8), arthritis (n = 6), oral ulcer-
ation (n = 4) and recent alopecia (n = 1). One patient had
concomitant HSV esophagitis that was treated with
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Acyclovir [46]. The mean SLEDAI score was 14.6 (range:
3–19) for the 64 patients in whom this data was reported.
When a long-term treatment for SLE was reported (89
cases), patients were on low dose corticosteroids (median
dose of equivalent prednisone: 10 mg per day, range 5–15
mg); five patients were on HCQ while they presented the
first episode of enteritis. Two patients (with known lupus)
developed enteritis shortly after delivery [26]. No pa-
tients presented concomitant pancreatitis and enteritis.
None of the patients exhibited signs of concurrent cuta-
neous vasculitis.
Laboratory data
When relevant laboratory data were available (n = 48), pa-
tients presented hematological anomalies including anemia
(52%) (3 had a positive Coombs test), leukocytopenia and/
or lymphocytopenia (40%) and thrombocytopenia (21%).
Median C-Reactive Protein (CRP) value (reported in 16
cases) was 2.0 mg/dL (range 0–8.2 mg/dL). Hypocom-
plementemia was reported in 30 of 34 cases (88%). When
autoimmune profile was discussed (n = 94), ANA were
positive in 92% and ds-DNA in 74%. Anti-RNP was posi-
tive in 28%, anti-SSA in 26% and anti-Sm antibodies in
24%. When urinary analysis was mentioned (n = 43), sig-
nificant proteinuria (>0.5 g/24 h or ++ on dipstick) was
present in 47%. Mean serum protein was 5.7 g/dL (17 pa-
tients). One patient had renal failure [43]; another had
elevated transaminases and amylase [29]. Positive aPL
antibodies were detected in 25/84 patients (30%). Seven pa-
tients fulfilled diagnostic criteria for the aPL syndrome.
One patient had cryoglobulin [31] (type not mentioned);
no patient had positive ANCA reported. When analyzed
(n = 9), ascites was a sterile exudate, unless perforation had
occurred (1 case) [14].
Imaging
Abdominal CT scanning was performed in 132 of 150
patients (88%). Other imaging modalities included plain
or contrast enhanced abdominal X-ray (22/150 patients,
15%), abdominal echography (10/150, 7%) and mesen-
teric angiography (5/150, 3%). One patient was diag-
nosed with lupus enteritis on capsule endoscopy. All
patients underwent small bowel imaging using at least
one imaging modality. Therefore, in all patients lupus
enteritis was diagnosed on the basis of a confirmed
diagnosis of SLE, and on both clinical and radiological
signs of lupus enteritis, by one or more of the available
imaging modalities. The most frequent radiographic
anomalies (repeat imaging on recurrence included) were
bowel wall edema (161/176, 91% of all episodes; 151/
159, 95% of CT images), abnormal bowel-wall enhance-
ment (double halo or target sign) in 68/96 (71%) and
dilatation of bowel lumen in 43/176 (24%). Ascites was
observed in (71/91, 78%). Mesenteric abnormalities such
as engorgement of mesenteric vessels, increased number
of visible vessels (comb sign), and increased attenuation
of mesenteric fat were present in 68/96 (71%). No pa-
tient had evidence for mesenteric thrombosis on CT.
One patient presented diminished mesenteric blood flow
on angiography, linked by the authors to histologically
confirmed small vessel vasculitis [15]. Seventeen percent
had digestive endoscopy (25/150), with normal macro-
scopic findings in 60%. One patient underwent capsule
endoscopy, revealing multiple small ulcers and scars
[20]. When the distribution of intestinal involvement
was detailed, jejunum and ileum were the most frequent
implicated segments (83 and 84% respectively), followed
by colon (19%), duodenum (17%) and rectum (4%). Four
percent (6/150) of patients developed pneumatosis intes-
tinalis. Eight patients presented urinary bladder wall
edema (lupus cystitis) concomitant with enteritis, which
was linked to an associated hydronephrosis in five.
Pathology
Thirty-four patients underwent biopsy, either endoscopic
or surgically. Macroscopic findings were described as
segmental areas of edematous (n = 8), hyperemic (n = 2) or
ischemic (n = 1) bowel with or without ulceration (n = 5),
necrosis (n = 3), wall thinning (n = 2) or perforation (n = 1).
Two patients had white nodules or plaques on the peri-
toneal surface [31,47]. Microscopic findings included cel-
lular infiltration of the submucosal (n = 2) and muscular
Table 2 Clinical, Laboratory & Imaging features of lupus
enteritis
Clinical Laboratory Imaging
Abdominal pain ANA, Anti ds-DNA Bowel abnormalities
(edema, target sign,
dilated lumen),
predominantly jejunum
and ileum
Ascites Low complement Ascites
Nausea Moderate elevated CRP Mesenteric abnormalities
(engorgement of
mesenteric vessels, comb
sign, increased
attenuation of
mesenteric fat)
Vomiting Leukopenia,
Lymphocytopenia,
Anemia,
Thrombocytopenia
Diarrhea Proteinuria
Active SLE features
Surgical abdomen
Fever
None of these features are specific. ANA: antinuclear antibodies; Ds-DNA:
Double stranded DNA; CRP: C-reactive protein; Target sign: Abnormal bowel
wall enhancement; Comb sign: Increased number of visible mesenteric vessels.
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(n = 2) layers with or without edema (n = 3) or vasculitis.
Hemorrhage was present in the muscular and subserosal
layers in 2 cases. Nine patients [1,11,12,15,16,18,29,37,48]
who underwent biopsy had straightforward histologic vas-
culitis (26% of biopsies, 9/150, 6% of population), con-
firmed exclusively on laparotomy. Vasculitis has been
characterized as necrotizing vasculitis with fibrinoid necro-
sis (n = 5), with panmural (n = 1) predominant eosinophilic
(n = 2), neutrophilic (n = 1) or mixed (n = 1) infiltrate. Ves-
sels in submucosal (n = 6), muscular (n = 4) and serosal
(n = 3) layers as well as mesenteric vessels (n = 2) were af-
fected. Both arterioles and venules (n = 1) could be affected
or in contrast a pattern of involvement of veins and ve-
nules with sparing of arteries (n = 1) was reported. One
patient had vasculitis of the polyarteritis nodosa type
(medium size vessels). Microvascular thrombus formation
was reported in 3 cases [14,16,47]. One of these patients
had aPL antibodies (low positive anticardiolipin); none
had diagnostic criteria for the aPL syndrome [49]. Other
findings included complement deposition on immuno-
fluorescence in intestinal veins and basement mem-
brane (n = 1) [48].
Treatment-outcome
Detailed treatment is shown in Additional file 1: Table
S1. All patients received corticosteroids as initial treat-
ment, either intravenous (IV) or oral (PO). IV corticoste-
roids (122/141, 87 %) in form of methylprednisolone
were administered in doses ranging from 40 mg per day
over 1 mg/kg per day to 30 mg/kg per day in a fatal
pediatric case [19]. Average duration of IV treatment
was 4 days, ranging from 1 to 34 days, commonly until
clinical improvement was obtained. When oral steroids
were chosen as initial treatment (19/141 13%), prednis-
olone was delivered in doses ranging from 20 mg per
day to 2 mg/kg per day, tapered over several weeks to
months to a median daily maintenance dose of 5 mg
(range 5–20 mg). Ninety-four (141/150) percent of pa-
tients received corticosteroids alone. Additional immuno-
suppression on initial treatment (n = 11) consisted of PO
(n = 1) or IV cyclophosphamide (CYC) at 500 mg/m2 to
750mg/m2. This was justified by concomitant severe organ
involvement in 5 (central nervous system involvement in
2 [32,43], lupus nephritis in 3 [18,47]), associated intes-
tinal necrosis in 4 [12,19,29,35,37] and persistent abdom-
inal pain despite of IV steroids in one patient [12].
Seventeen patients underwent laparotomy, of which 10
(7%) had resection for necrosis or perforation.
Evolution
Relief of symptoms took typically less than a week (range:
2 days to 8 weeks), with parallel biological and radiological
normalization. Long-term maintenance therapy after a
first episode (other than prednisolone) consisted of HCQ
(n = 7), MMF (n = 3), azathioprine (AZA) (n = 2) and oral
chlorambucil (n = 1).
Recurrence, i.e. more than one episode of enteritis,
was reported in 34 patients (23%) with a median num-
ber of 3 episodes (range: 2–9). When we considered
patients with reported observance of at least 1 year
(n = 30), recurrences occurred in 25%. On recurrent epi-
sodes, corticosteroids were used similar to first epi-
sodes. Additional immunosuppression consisted of IV
CYC (n = 4) [1,25,43,44], MMF (n = 4) [25,34,44], AZA
(n = 4) [25,34,43], Rituximab (n = 2) [34,44] and PO
CYC (n = 1) [34]. Declared morbidity included short
bowel syndrome with home total parenteral nutrition
(n = 1) [37], recurrent abdominal bloating and dyspepsia
(n = 1) [25] and recurrent abdominal pain without im-
aging abnormalities (n = 2). Four patients died after a
median follow-up of 18 months, yielding a mortality
rate of 2.7%. Reported causes of death included diffuse
necrosis of intestinal tract (n = 1) [14], associated neuro-
logic complications (n = 1) [11] and sepsis (n = 1) [19].
Discussion
Lupus enteritis is a potentially severe complication of
SLE, stressing the need for swift diagnosis and adequate
management. The literature on the subject consists en-
tirely out of case reports and case series, and no con-
trolled studies on treatment are yet available. Here, we
have reported 7 new cases of lupus enteritis and thor-
oughly reviewed 143 cases from the literature to draw
out recommendations for the diagnosis and manage-
ment of this unusual complication of SLE.
The clinical picture of lupus enteritis is non-specific,
with abdominal pain being the cardinal manifestation,
sometimes accompanied by symptoms and signs of im-
paired intestinal motility or peritonitis. Other elements
of active lupus [50] are universally present. Buck et al.
[51] found that only patients with active disease (SLEDAI
score >8) and acute abdominal pain were diagnosed with
“lupus mesenteric vasculitis”, but Lee et al. [30] found no
difference in SLEDAI scores between lupus enteritis and
other causes of abdominal pain in 175 lupus patients,
suggesting that SLEDAI score is not suited for differencing
the cause of abdominal pain in active lupus. It is note-
worthy that the SLEDAI score contains no items to score
abdominal SLE disease activity, in contrast to the British
Isles Lupus Assessment Group (BILAG) index [52].
CT scanning has become the gold standard for diagno-
sis of lupus enteritis. One should keep in mind that in
SLE patients, who are commonly treated with corticoste-
roids, signs of perforation might be clouded; conse-
quently, the threshold for radiographic evaluation should
be low. Typical features of lupus enteritis include focal
or diffuse bowel-wall thickening, bowel dilation, abnor-
mal bowel wall enhancement (target sign), engorgement
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of mesenteric vessels with increased number of visible
vessels (comb’s sign), increased attenuation of mesen-
teric fat and ascites [15,27]. Bowel wall involvement is
mostly multisegmental and not confined to a single vas-
cular territory [1], with jejunum and ileum being the
most commonly involved sites. However, the lack of spe-
cificity of CT signs is a limitation, as the above described
abnormalities can also be seen in patients with pancrea-
titis, mechanical bowel obstruction, peritonitis, or inflam-
matory bowel disease, all of which may mimic intestinal
ischemia [53]. Abdominal ultrasound seems to be an ele-
gant tool to confirm bowel edema or ascites and might be
useful to confirm straightforward clinical diagnosis or al-
ternatively in follow-up to affirm clinical recovery. Endo-
scopic biopsies are not very rewarding, possibly because
only superficial tissue is obtained or due to sample effect.
We suggest that these should be used primarily to confirm
or rule out alternative diagnoses rather than to confirm
vasculitis. None of our 7 new cases underwent biopsy of
the affected intestinal tract.
No single biological finding can be considered pathogno-
monic for lupus enteritis. CRP is typically not very elevated
and high CRP should be considered suggestive for an alter-
native cause of abdominal pain or infectious complications
[54]. Twenty-eight percent of patients with lupus enteritis
had positive aPL biology, which is compatible with the
background prevalence of aPL antibodies in SLE [55].
Three patients had thrombosis on histology and only one
of them had weak positive anticardiolipin antibodies. Two
studies [1,30] found no differences in autoantibody profiles
including those of aPL antibody between SLE patients with
lupus enteritis and other causes of abdominal pain. Thus it
seems unlikely that thrombosis in the context of the aPL
syndrome is involved in lupus enteritis.
In the BILAG 2004, lupus enteritis is defined as either
vasculitis or inflammation of the small-bowel. Although
Figure 2 Therapeutic strategy for lupus nephritis. CNS: central nervous system; IV: intravenous; HCQ: hydroxychloroquine; AZA: azathioprine;
MMF: mycophenolate mofetil.
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lupus enteritis is commonly considered a form of vis-
ceral or serosal vasculitis, this is seldom confirmed on
histology. Only 9 patients (6%) had clear histological con-
firmation of vasculitis. Drenkard [56] reported only one
case of mesenteric vasculitis among 667 patients with vas-
culitis in SLE. Consequently, we advocate the use of the
generic term enteritis rather than vasculitis. Other than
being merely a non-specific biological sign of active SLE,
the frequently encountered hypocomplementemia in lupus
enteritis might be a consequence of immune-complex-me-
diated vasculitis in the development of lupus enteritis [57].
In the single case where immunofluorescence was
reported, complement deposition in mesenteric small ves-
sels was found [48]. Independent of potential pathogen-
esis, events eventually lead to edema, bleeding and
necrosis, translating into clinical symptomatology of pain,
diarrhea, bleeding, obstruction and perforation. Peritoneal
irritation, whether primary (serositis) or secondary (intes-
tinal vasculitis), can lead to ascites [58].
Lupus enteritis is generally reversible and steroid-
responsive. Previous studies [1] failed to identify factors
that could predict therapy-resistant or relapsing forms of
enteritis. Early surgical intervention rather than steroid
therapy as a treatment for lupus enteritis has been advo-
cated [6], but does not seem legitimate in view of high
steroid responsiveness, reversibility and limited morbid-
ity and mortality. We would rather encourage extreme
vigilance for perforation and peritonitis with low thresh-
old for (repeat) CT imaging and early laparoscopy or
laparotomy to evaluate intestinal viability in case of
doubt. Abdominal paracentesis for ascites does not seem
to be very useful unless there is doubt about its etiology
or as a therapeutic measure if abundant.
Well-aware of the absence of any prospective con-
trolled studies on treatment of lupus enteritis but merely
synthesizing therapies applied in the considered papers
we propose a therapeutic strategy, ideally to be tested in
future controlled studies (Figure 2). Based on the high
steroid-responsiveness, corticosteroids appear to be the
first line treatment of lupus enteritis. These may be ad-
ministered IV or PO based on clinical status or other
organ involvement, with preference for IV in case of se-
vere lupus flare because of potentially reduced drug ab-
sorption due to enteritis [59]. CYC or MMF might be
added in case of resistance to corticosteroids or when
warranted by other organ involvement. Treatment can
be switched to oral corticosteroids as soon as adequate
clinical improvement occurs, with tapering according to
clinical evolution. HCQ, MMF, AZA and low dose corti-
costeroids could be considered for long-term mainten-
ance treatment, although it is unknown whether they
may prevent recurrences. In recurrent forms MMF,
AZA, CYC and Rituximab have been successfully used
to prevent further recurrence, in a limited number of
cases. In absence of controlled studies [60] the choice
for a particular immunosuppressive regimen should be
based on individual benefit-risk ratio, considering other
organ involvement or a potential pregnancy wish. Sup-
portive measures include bowel rest, IV fluids and proton
pump inhibitors. Heparin might be added in presence of
aPL antibodies and suspicion of aPL syndrome. Early
laparoscopy or laparotomy should be considered if necro-
sis or perforation is suspected.
Conclusion
Lupus enteritis is a rare complication of SLE. Diagnosis
is based on typical CT findings (bowel wall edema with
target sign, mesenteric abnormalities and ascites) in SLE
patients with acute abdominal pain. Lupus enteritis is
typically steroid-responsive with an overall excellent
prognosis. Immunosuppressive treatment is reserved for
recurrent enteritis or severe SLE cases. We advocate
simplifying nomenclature by the use of the single term
“lupus enteritis” and we propose better-defined diagnos-
tic criteria to limit heterogeneity. Finally, we stress the
need for a prospective evaluation of this rare disease by
encouraging establishment of an international register.
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